参考文献/References:
[1] BRAY F,FERLAY J,SOERJOMATARAM I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality Worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
[2] 国家肿瘤质控中心乳腺癌专家委员会,中国抗癌协会乳腺癌专业委员会,中国抗癌协会肿瘤药物临床研究专业委员会.中国晚期乳腺癌规范诊疗指南(2020)[J].中华肿瘤杂志,2020,42(10):781-797.
BREAST CANCER EXPERT COMMITTEE OF NATIONAL CANCER QUALITY CONTROL CENTER,BREAST CANCER EXPERT COMMITTEE OF CHINA ANTI-CANCER ASSOCIATION,CANCER DRUG CLINICAL RESEARCH COMMITTEE OF CHINA ANTI-CANCER ASSOCIATION.Guidelines for clinical diagnosis and treatment of advanced breast cancer in China (2020 edition)[J].Chin J Oncol,2020,42(10):781-797.
[3] 金玉芬,张婷,姜新,等.B7-H3在结直肠癌中的研究进展[J].癌症进展,2020,18(17):1740-1743,1829.
JIN Y F,ZHANG T,JIANG X,et al.Research progress of B7-H3 in colorectal cancer[J].Cancer Progress,2020,18(17):1740-1743,1829.
[4] 刘德总,杨颖涛.乳腺癌辅助治疗现状与展望[J].新乡医学院学报,2021,38(8):781-789,793.
LIU D Z,YANG Y T.Current situation and prospect of adjuvant therapy for breast cancer[J].J Xinxiang Med Univ,2021,38(8):781-789,793.
[5] 杨永昌,常帅,刘杰.免疫检查点分子B7-H3在肿瘤中作用的研究进展[J].标记免疫分析与临床,2021,28(4):692-696.
YANG Y C,CHANG S,LIU J.The research progress of immune checkpoint B7-H3 in tumor[J].Labeled Immunoassay Clin Med,2021,28(4):692-696.
[6] 王萱,南丁阿比雅思,杨悦,等.B7-H3的作用机制及其在非小细胞肺癌中的研究新进展[J].现代肿瘤医学,2019,27(24):4485-4488.
WANG X,NADINGABIYASI,YANG Y,et al.New progress on the mechanism of B7-H3 and its clinical significance in non-small cell lung cancer[J].J Mod Oncol,2019,27(24):4485- 4488.
[7] 董贺婷,陈正荣,季伟.可诱导共刺激分子配体的研究进展[J].江苏医药,2020,46(2):195-198.
DONG H T,CHEN Z R,JI W.Research progress of inducible costimulatory molecular ligands[J].Jiangsu Med J,2020,46(2):195-198.
[8] ZHENG Y,LIAO N,WU Y,et al.High expression of B7-H2 or B7-H3 is associated with poor prognosis in hepatocellular carcinoma[J].Mol Med Rep,2019,19(5):4315-4325.
[9] DESANTIS C E,MA J,GAUDET M M,et al.Breast cancer statistics,2019[J].CA Cancer J Clin,2019,69(6):438-451.
[10] 张佳,李宏江.乳腺癌免疫检查点抑制剂研究进展[J].西部医学,2021,33(11):1708-1713.
ZHANG J,LI H J.Progress in immunocheckpoint inhibitors for breast cancer[J].Med J West Chin,2021,33(11):1708-1713.
[11] MITTENDORFE A,PHILIPS A V,MERICBER N,et al.PD-L1 expression in triple-negative breast cancer[J].Cancer Immunol Res,2014,2( 4):361-370.
[12] 王晓稼.乳腺癌的免疫治疗策略[J].中国肿瘤外科杂志,2020,12(4):301-305.
WANG X J.Immunotherapy strategies for breast cancer[J].Chin J Surg Oncol,2020,12(4):301-305.
[13] EMENS L A,ADAMS S,BARRIOS C H,et al.First-line atezolizumab plus nab-paclitaxel for unresectable,locally advanced,or metastatic triple-negative breast cancer:IMpassion130 final overall survival analysis[J].Ann Oncol,2021,32(8):983-993.
[14] CORTES J,CESCON D W,RUGO H S,et al.Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355):a randomised,placebo-controlled,double- blind,phase 3 clinical trial[J].Lancet,2020,396(10265):1817-1828.
[15] DI SPAZIO L,RIVANO M,CANCANELLI L,et al.The degree of programmed death-ligand 1(PD-L1) positivity as a determinant of outcomes in metastatic triple-negative breast cancer treated with first-line immune checkpoint inhibitors[J].Cureus,2022,14(1):e21065.
[16] TOLANEY S M,BARROSO-SOUSA S R,KEENAN T,et al.Effect of eribulin with or without pembrolizumab on progression-free survival for patients with hormone receptor-positive,ERBB2-negative metastatic breast cancer:a randomized clinical trial[J].JAMA Oncol,2020,6(10):1598-1605.
[17] WANG F,YAN T,CHEN L,et al.Involvement of inducible costimulator ligand (ICOSL) expression in thyroid tissue in hyperthyroidism of Graves′ disease patients[J].J Clin Immunol,2012,32(6):1253-1261.
[18] 曹婷华.结直肠癌微环境中B7-H2在CD8+T细胞的表达及临床意义[D].苏州:苏州大学,2017.
CAO T H.Expression of B7-H2 in CD8+T cells in colorectal cancer microenvironment and its clinical significance[D].Suzhou:Soochow Univ,2017.
[19] 马晓天,郭振红.共信号分子功能及其在肿瘤治疗中的应用[J].中国肿瘤生物治疗杂志,2021,28(12):1219-1226.
MA X T,GUO Z H.The functions of co-signaling molecules and their clinical applications in cancer therapy[J].Chin J Cancer Biother,2021,28(12):1219-1226.
[20] SOLINAS C,GU-TRANTIEN C,WILLARD-GALLO K.The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy[J].ESMO Open,2020,5(1):e000544.
[21] KUMAWAT A K,STRID H,TYSK C,et al.Microscopic colitis patients demonstrate a mixed Th17/Tc17 and Th1/Tc1 mucosal cytokine profile[J].Mol Immunol,2013,55(3-4):355-364.
[22] CURIEL T J,COUKOS G,ZOU L,et al.Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival[J].Nat Med,2004,10(9):942-949.
[23] KANG F B,WANG L,JIA H C,et al.B7-H3 promotes aggression and invasion of hepatocellular carcinoma by targeting epithelial-to-mesenchymal transition via JAK2/STAT3/Slug signaling pathway[J].Cancer Cell Int,2015,15:45.
[24] 何桦波,武伟,徐静芳.外周血B7-H2联合白细胞介素-6水平变化在胆管癌诊断及预后评估中的价值[J].中国卫生检验杂志,2019,29(11):1334-1336,1339.
HE H B,WU W,XU J F.The value of peripheral blood B7-H2 combined with interleukin 6 level in the diagnosis and prognosis of cholangiocarcinoma[J].Chin J Health Lab Technol,2019,29(11):1334-1336,1339.
[25] WANG B,JIANG H Y,ZHOU T Y,et al.Expression of ICOSL is associated with decreased survival in invasive breast cancer[J].Peer J,2019,7:e6903.
[26] ZHANG G,XU Y,ZHANG S,et al.The ICOSL expression predicts better prognosis for nasopharyngeal carcinoma via enhancing oncoimmunity[J].Biomed Res Int,2020,2020:9756732.
[27] WANG L,KANG F B,SHAN B E.B7-H3-mediated tumor immunology:friend or foe[J].Int J Cancer,2014,134(12):2764-2771.
[28] CHAPOVAL A I,NI J,LAU J S,et al.B7-H3:a costimulatory molecule for T cell activation and IFN-gamma production[J].Nat Immunol,2001,2(3):269-274.
[29] KIM J Y,LEE E,PARK K,et al.Immune signature of metastatic breast cancer:identifying predictive markers of immunotherapy response[J].Oncotarget,2017,8(29):47400-47411.
[30] 于超.乳腺癌患者血清中sB7-H3相关临床价值的初步研究[D].青岛:青岛大学,2020.
YU C.Preliminary study on the clinical value of sB7-H3 in serum of breast cancer patients[D].Qingdao:Qingdao University,2020.
[31] 杜贞华.可溶性B7-H3在乳腺癌血清中的表达及意义[D].济南:山东大学,2011.
DU Z H.The expression of serum soluble B7-H3 in breast cancer and the clinical significance[D].Jinan:Shandong University,2011.
相似文献/References:
[1]张光谋,吴俊琢,徐振平,等.抗细胞凋亡基因bcl一2在乳腺癌中的表达[J].新乡医学院学报,2001,18(03):160.
[2]刘玉生 . 万里,李森恺.乳腺癌切除即期乳房再造[J].新乡医学院学报,2001,18(01):023.
[3]王承正,张锦瑜,邱树升,等.C—erbB一2与ER、PS一2在乳腺癌中的表达及其临床相关性[J].新乡医学院学报,2003,20(05):324.
[4]王承正,张锦瑜,邱树升,等.C2erbB22 与ER、PS22 在乳腺癌中的表达及其临床相关性[J].新乡医学院学报,2003,20(05):324.
[5]王志民,段西华,祁天义,等.多点皮瓣固定法预防乳腺癌术后皮下积液效果观察 [J].新乡医学院学报,2007,24(03):287.
[6]郭兰青.乳腺癌患者生活质量影响因素[J].新乡医学院学报,2008,25(06):637.
[7]曹兴玥,赵庆伟,靳艳,等.CD44和nm23在乳腺浸润性导管癌中的表达及其与淋巴结转移的关系[J].新乡医学院学报,2011,28(01):042.
[8]靳艳,曹兴玥,赵庆伟,等.CD62P在人乳腺癌组织中的表达及其与淋巴结转移的关系[J].新乡医学院学报,2011,28(01):045.
[9]王 乐,王静萱,张清媛.乳腺癌骨转移靶向治疗进展[J].新乡医学院学报,2015,32(09):887.
[10]杨绍英,刘朝荣,张志刚,等.乳腺癌新辅助化学治疗前后雌激素受体、乳激素受体、Ki-67抗原和人类表皮生长因子受体-2的表达[J].新乡医学院学报,2017,34(2):125.[doi:10.7683/xxyxyxb.2017.02.012]
YANG Shao-ying,LIU Chao-rong,ZHANG Zhi-gang,et al.Expressions of estrogen receptor,progestin recetor,Ki-67 antigen,and human epidermal growth factor receptor 2 before and after neoadjuvant chemotherapy in patients with breast cancer[J].Journal of Xinxiang Medical University,2017,34(9):125.[doi:10.7683/xxyxyxb.2017.02.012]